bluebird bio
NEWS
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.
Tuesday, January 8, was another busy day in San Francisco for the JP Morgan Healthcare Conference. One interesting sideline was the idea that the current government shutdown could complicate some deals.
For a moment, simply contemplate the possible price: $2.1 million for a drug. It’s not just any drug, however. Cambridge, Mass.-based bluebird bio’s LentiGlobin is a gene therapy being evaluated for transfusion-dependent ß-thalassemia.
The JP Morgan Healthcare Conference, being held from January 7 through 10 at the Westin St. Francis Hotel in San Francisco, is one of the premier, possible the premier, conferences for the biopharmaceutical industry.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Winter and the Holidays are right around the corner, but don’t stop your job search! Check out the top companies who are looking for candidates like you right now!
Janssen Pharmaceutical, a Johnson & Johnson company, along with Legend Biotech, reported results from their LEGEND-2 Phase I/II clinical trial of CAR-T therapy LCAR-B38M. The therapeutic was being investigated in patients with advanced relapsed or refractory (r/r) multiple myeloma.
At the American Society of Hematology meeting, companies are racing to develop a treatment for SCD, which is an inherited disorder caused by a genetic mutation in the beta-chain of hemoglobin. Some of the data presented by companies were promising, while others reported setbacks.
JOBS
IN THE PRESS
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: 9 th Annual SVB Leerink Global Healthcare Conference, Wednesday, February 26, at 2:30 p.m. ET at the Lotte New York Palace, New York, NY
First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in January
CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18
More than four years of durable transfusion independence (TI), stable total hemoglobin (Hb) levels and reduced liver iron concentrations in completed Phase 1/2 Northstar (HGB-204) study in patients who do not have a β0/β0 genotype
99% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with history of VOCs and ACS who had at least six months follow-up, no reports of ACS or serious VOCs at up to 21 months post-treatment
Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 3052538.
bluebird bio, Inc. and Forty Seven, Inc. announced that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 plus magrolimab, with bluebird’s ex vivo lentiviral vector hematopoietic stem cell gene therapy platform.
Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma
Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust development pipeline